常山药业(300255) - 2019 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2019 reached ¥458,732,011.25, an increase of 39.68% compared to ¥328,413,253.38 in the same period last year[8] - Net profit attributable to shareholders was ¥56,655,872.70, up 24.85% from ¥45,379,800.76 year-on-year[8] - Net profit after deducting non-recurring gains and losses was ¥53,797,594.86, reflecting a 21.59% increase from ¥44,244,873.83 in the previous year[8] - Basic earnings per share increased by 20.00% to ¥0.06 from ¥0.05 year-on-year[8] - The company's operating revenue for Q1 2019 reached 458.73 million CNY, a year-on-year increase of 39.68% driven by market promotion and increased sales of heparin products[24] - The net profit attributable to shareholders for Q1 2019 was 56.66 million CNY, reflecting a 24.85% increase compared to the same period last year[26] - The company's total comprehensive income attributable to the parent company was ¥58,802,105.75, up from ¥45,379,800.76 in the previous year, indicating strong overall performance[72] Cash Flow - The net cash flow from operating activities was -¥128,727,834.88, a decline of 54.07% compared to -¥83,550,267.88 in the same period last year[8] - The company's cash flow from operating activities showed a net outflow of 54.07% compared to the same period last year, primarily due to increased cash payments related to operating activities[25] - Cash inflow from operating activities totaled CNY 479,857,852.40, compared to CNY 442,711,438.05 in the prior period, indicating an increase of about 8.4%[82] - Net cash flow from operating activities was negative at CNY -128,727,834.88, worsening from CNY -83,550,267.88 in the previous period[82] - Cash outflow from operating activities reached CNY 608,585,687.28, up from CNY 526,261,705.93, representing an increase of approximately 15.6%[82] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,880,761,932.36, a slight increase of 0.93% from ¥3,844,836,970.34 at the end of the previous year[8] - Net assets attributable to shareholders rose to ¥2,571,620,233.27, up 2.34% from ¥2,512,818,127.52 at the end of the last year[8] - The total amount of procurement from the top five suppliers was 81.39 million CNY, accounting for 54.87% of total procurement, indicating normal fluctuations without significant impact on future operations[28] - The total amount of sales to the top five customers was 88.38 million CNY, representing 19.27% of total sales revenue, with no significant reliance on any single customer[28] - The total liabilities decreased from 1,321,811,944.11 to 1,299,819,756.23, a reduction of approximately 1.4%[52] - The total owner's equity increased from 2,523,025,026.23 to 2,580,942,176.13, reflecting a growth of about 2.3%[55] Research and Development - The company's research and development expenses increased by 32.11% year-on-year, reflecting a commitment to enhancing R&D investment[24] - Research and development expenses increased to ¥23,932,784.13, up 32.3% from ¥18,115,124.71 in the prior period, indicating a focus on innovation[66] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,530[11] - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, totaling 333,644,728 shares[11] Government Subsidies - The company received government subsidies amounting to ¥3,553,780.96 during the reporting period[8] - The company reported a significant increase of 138.45% in other income, mainly due to increased government subsidies related to operating activities[25] Inventory and Receivables - Accounts receivable increased to approximately CNY 374 million from CNY 345 million, reflecting a growth of about 8.5%[46] - Inventory levels rose to approximately CNY 1.15 billion, up from CNY 1.08 billion, indicating an increase of about 6.3%[46] Financial Management - The company experienced a tax expense of ¥9,479,060.22, slightly down from ¥10,215,198.75 in the previous period, suggesting effective tax management[69] - The company has not encountered any violations regarding external guarantees during the reporting period[41] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[42] Financial Standards and Audits - The company has not yet audited its first-quarter report, indicating that the figures are preliminary[102] - The company has implemented new financial instrument and revenue recognition standards, affecting the financial statements[93]